Press release
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analysis
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature cardiovascular diseases. About 1 in 250 people around the world have HeFH and only about 10% of people with this medical condition have been diagnosed. Diagnosis is important because there are several early aggressive treatments available which can lower the risk for heart diseases or stroke.
Get the detailed analysis @ https://www.pharmaproff.com/report/hefh-therapeutics-pipeline-analysis
The drug candidates of HeFH pipeline include, but not limited to, GEM-201 and anacetrapib. Some of the other companies having drugs in the HeFH pipeline includes Gemphire Therapeutics Inc. and Merck & Co. Inc.
Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1135
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analysis here
News-ID: 1727305 • Views: …
More Releases for HeFH
Pediatric Medicines Market Overview by Recent Opportunities, Growth Size, Region …
The global pediatric medicines market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Pediatric medicines is a branch of medicines that deals with the development, care for the management of diseases associated with infants, children, and adolescents. The major factor driving the growth of the market include the rising birth rate across the globe.
Moreover, the market is also growing owing to new drug approvals.…
Insights on the Heterozygous Familial Hypercholesterolemia Drug Market to 2027 | …
The global heterozygous familial hypercholesterolemia drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder. It causes high cholesterol levels that lead to heart disease, heart attack, or stroke. Additionally, HeFH is one form of Familial Hypercholesterolemia (FH). The major factor driving the demand for the heterozygous familial hypercholesterolemia drug is the increasing prevalence of familial…
Heterozygous familial hypercholesterolemia Disease Market Report- Rising Demand, …
Heterozygous familial hypercholesterolemia Disease Market research report provides top-notch information on the global transformer oil market based on type, application, end-user, and region. Heterozygous familial hypercholesterolemia Disease Market offers qualitative and quantitative market analysis, including market drivers, restraints, obstacles, and opportunities in the market. In addition, Heterozygous familial hypercholesterolemia Disease Market provides a region-wise assessment of the need to understand the competitive landscape, market trends, and market dynamics.
Get FREE PDF…
Wearable Injectors Market Insights on Future Growth Prospects and Industry Trend …
Looking at the current market trends as well as the promising demand status of the “Wearable Injectors market”, it can be projected that the future years will bring out positive outcomes. This research report added by MRRSE on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application; assisting them…
Wearable Injectors Industry Application Investigates Growth Inclinations for the …
Market Research Reports Search Engine (MRRSE) has recently updated its massive report catalogue by adding a fresh study titled “Wearable Injectors Industry Application Investigates Growth Inclinations for the Period until 2026”. This business intelligence study encapsulates vital details about the market current as well as future status during the mentioned forecast period of 2026.The report also targets important facets such as market drivers, challenges, latest trends, and opportunities associated to…
Hyperlipidemia Therapeutics Pipeline - Key Players Analysis Novartis, Eli Lilly …
Hyperlipidemia refers to elevated amount of lipids and cholesterol in the bloodstream. The two major types of lipid abnormalities are characterized by either high blood levels of triglycerides (known as hypertriglyceridemia) or high blood cholesterol levels (known as hypercholesterolemia). Hyperlipidemia is often associated with increased risk of coronary heart disease and strokes. The study analyzed that hyperlipidemia therapeutics pipeline comprises 53 drug candidates in different stages of development.
Browse report sample…
